Drug profile · INN
laropiprant
TREVACLYN
laropiprant (TREVACLYN) is a prostanoid dp receptor antagonist.
EMA: withdrawn Cardiovascular system (C10) C10AD52
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — laropiprant
- Class
- Cardiovascular system (C10)
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.83
Quick answer
laropiprant (TREVACLYN) is a prostanoid dp receptor antagonist.
Key facts
INN laropiprant
Brand TREVACLYN
Mechanism Prostanoid DP receptor antagonist
Target Prostaglandin D2 receptor
Therapeutic class Cardiovascular system (C10)
ATC code C10AD52
Mechanism of action
Prostanoid DP receptor antagonist
Primary target: Prostaglandin D2 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | withdrawn | — |
Related & competitor drugs
Frequently asked questions
What is laropiprant?
laropiprant (TREVACLYN) is a prostanoid dp receptor antagonist.
What is the brand name for laropiprant?
TREVACLYN is a marketed brand name for laropiprant. Check FDA Drugs@FDA for the current US label holder and prescribing information.